<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615758</url>
  </required_header>
  <id_info>
    <org_study_id>CT/06.03</org_study_id>
    <nct_id>NCT00615758</nct_id>
  </id_info>
  <brief_title>Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV</brief_title>
  <official_title>ERLOTINIB, A TYROSINE KINASE INHIBITOR OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AS FIRST LINE TREATMENT, IN PATIENTS WITH LOCALLY ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER (NSCLC). A PHASE II STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Oncology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hellenic Oncology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and toxicity of erlotinib as first line treatment in patients with&#xD;
      locally advanced/metastatic (stages IIIB/IV) NSCLC, with clinical predictors of response to&#xD;
      tyrosine kinase inhibitors (erlotinib, gefitinib), such as female gender, never-smoking&#xD;
      status and adenocarcinoma histology. Furthermore, erlotinib-sensitivity will be correlated&#xD;
      with the presence of EGFR mutations in exons 18, 19 and 21, in this population&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, placebo-controlled phase III trial of erlotinib versus placebo, with more than&#xD;
      700 patients demonstrated that therapy with this tyrosine kinase inhibitor (TKI) prolongs&#xD;
      survival after first or second line therapy in patients with advanced NSCLC. Statistically&#xD;
      significant and clinically relevant differences were observed for overall and progression&#xD;
      free survival in favour of erlotinib. Moreover, several clinical factors had been correlated&#xD;
      with response to gefitinib or erlotinib, including never smoking status, female gender, Asian&#xD;
      ethnicity and adenocarcinoma histology (especially bronchioalveolar carcinoma).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1-year OS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Progression</measure>
    <time_frame>1 year TTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity assesment</measure>
    <time_frame>Toxicity assessment on each cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tarceva</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib at the dose of 150 mg orally once a day continually until progression</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed, unresectable locally advanced (stage IIIB&#xD;
             with pleural effusion) and/or metastatic (stage IV) NSCLC&#xD;
&#xD;
          -  No previous therapy for advanced/metastatic NSCLC is allowed&#xD;
&#xD;
          -  age &gt;18 years&#xD;
&#xD;
          -  bidimensionally measurable disease&#xD;
&#xD;
          -  non-smokers (or ex-smokers with less than 5 pack-years smoking history)&#xD;
&#xD;
          -  adenocarcinoma histology&#xD;
&#xD;
          -  performance status (WHO) 0-3&#xD;
&#xD;
          -  adequate liver (serum bilirubin &lt;1.5 times the upper normal limit (UNL); AST and ALT&#xD;
             &lt;2.5 times the UNL in the absence of demonstrable liver metastases, or &lt;5 times the&#xD;
             UNL in the presence of liver metastases); adequate renal function (serum creatinine&#xD;
             &lt;1.5 times the UNL); and bone marrow (neutrophils ≥ 1.5x 109 /L, and platelets ≥ 100x&#xD;
             109 /L) function&#xD;
&#xD;
          -  previous radiotherapy, either in the adjuvant setting or for the treatment of&#xD;
             metastatic disease is allowed provided that the measurable lesions are outside the&#xD;
             radiation fields&#xD;
&#xD;
          -  patient able to take oral medication&#xD;
&#xD;
          -  tissue sample for tumour mutational analysis is required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serious chronic skin conditions (e.g. psoriasis, eczema) that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  active infection&#xD;
&#xD;
          -  history of significant cardiac disease (unstable angina, congestive heart failure,&#xD;
             myocardial infarction within the previous 6 months, ventricular arrhythmias)&#xD;
&#xD;
          -  malnutrition (loss of ≥ 20% of the original body weight)&#xD;
&#xD;
          -  performance status: 4&#xD;
&#xD;
          -  psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilis Georgoulias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Athanasios Pallis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>401 Military Hospital, Medical Oncology Unit</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Air Forces Military Hospital, Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO&quot; General Hospital of Athens, 1st Dep of Medical Oncology</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria&quot; General Hospital, 2nd Dep of Pulmonary Diseases</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Diabalkaniko&quot; Anticancer Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>December 14, 2009</last_update_submitted>
  <last_update_submitted_qc>December 14, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>V.Georgoulias</name_title>
    <organization>Hellenic Oncology Research Group</organization>
  </responsible_party>
  <keyword>Erlotinib</keyword>
  <keyword>Biological therapy</keyword>
  <keyword>Tyrosin Kinase Inhibitor therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

